The stock of Royalty Pharma plc (NASDAQ:RPRX) increased by $0.14 on Wednesday to $40.25, up 0.35 percent. The last five days have seen an average of 1,750,970 shares of common stock traded. 6 times new highs were reached in the current year, with a gain of $0.43. The average number of shares traded over the last 20 days was 1,794,223, while the average volume over the last 50 days totaled 2,285,195.
RPRX stock appreciated 0.83% since last month. On 06/16/22, the company’s shares reached a one-month low of $37.44. The stock touched a high of $44.75 on 04/14/22, after rallying from a low of $34.86 in 52 weeks. The price of RPRX stock has risen by 0.65% or $0.43 this year, reaching a new high 6 times. Still, the stock price is down -10.06% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
There have been 14 days since Royalty Pharma plc (RPRX) last reported insider trading activity on Jun 08. On Jun 08, EVP & Chief Scientific Officer Reddoch James F. sold 100,000 shares at $41.56 each. This transaction resulted in the insider making $4,155,900. On May 27, Reddoch James F. sold 75,000 shares at a price of US$41.08. After the transaction, the insider now owns 1,020,800 shares. EVP, Investments & GC Lloyd George W. had earlier sold 13,974 shares on May 27 for $40.77 a share. The transaction was completed for $569,754.
Royalty Pharma plc (RPRX) has a trailing price-to-earnings (P/E) ratio of 40.23. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 10.41, the price-to-book (PB) ratio of 3.01.
Company paid $0.19 per share in dividends, remained unchanged from $0.19 last year. A $0.02 dividend increase was reported on Thursday January 6 2022.
For the three months ended March 30, Royalty Pharma plc’s quick ratio was 22.00, while its current ratio was 22.00, indicating its ability to pay off its debt. Royalty Pharma plc’s operating margin stood at 62.40% for the same period. Based on annual data, it had gross profit of $858.75 million and revenue of $2.29 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. RPRX’s return on assets (ROA) during the last 12 months has been 3.50%. There was a 11.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 10.40%.
According to Royalty Pharma plc’s quarterly financial report for the quarter that ended March 30, it had $7.1 billion in total debt versus $549.02 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $562.05 million, while revenues fell by -1.95% to $575.7 million. It was predicted that Royalty Pharma plc’s quarterly earnings would be $0.6, but it ended up being $0.73, beating the consensus by -17.80%. EBITDA was $230.73 million for the quarter. At the end of Royalty Pharma plc’s most recent quarter ended March 30, its liabilities totaled 7.24 billion, while its total debt was $7.1 billion. Equity owned by shareholders amounts to $607.18 million.
Here’s a quick look at Royalty Pharma plc’s (RPRX) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 54.69%, suggesting the stock is Neutral, with a 33.87% historical volatility rate.
The stochastic %K and %D were 54.56% and 45.63% respectively, while the average true range (ATR) was 1.12. Based on the 14-day stochastic reading of 62.58%, the RSI (14) reading is 51.51%. On the 9-day MACD Oscillator, the stock is at 0.49, and the 14-day reading is at -0.02.
Analysts have assigned Royalty Pharma plc (RPRX) an Buy rating. RPRX is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 9 others recommend it as a buy.
What is RPRX’s price target for the next 12 months?
The current consensus forecast for the stock is between $47.00 and $58.00, with a median target price of $51.00. In analyzing these forecasts, the average price target given by analysts for Royalty Pharma plc (RPRX) is $52.44.